现代分子病理学的伦理考量
本文为视角文章,按肿瘤DNA测序分析的分析前、分析和分析后流程讨论分子病理学中的伦理问题。作者指出伦理关注落后于技术发展,现有指南多针对临床遗传或生物医学研究,实验室间测序分析流程差异大,并建议病理学家承担责任、充分认识并处理肿瘤DNA测序的伦理问题。
要点
- 分子病理伦理关注落后于技术发展,缺乏专门指南或出版物。
- 肿瘤DNA测序可能产生敏感且潜在相关的数据,如临床显著的非预期发现。
- 病理学家应对分子分析的适当使用负责并具备处理伦理问题的能力。
核心结论
- 为负责任地使用和进一步发展临床癌症诊疗,建议病理学家对分子分析的适当使用承担责任,并充分认识和处理肿瘤DNA测序的多样、复杂和具有挑战性的伦理问题。
研究设计与样本
- 本文为视角文章,按肿瘤DNA测序分析从分析前到分析后的流程讨论分子病理学中的伦理问题。
主要发现
- 分子病理学在肿瘤学中日益重要,分子肿瘤特征将日益决定靶向临床癌症诊疗。
- 伦理方面的关注一直落后,表现为缺乏出版物或专业指南。
- 现有关于DNA测序伦理方面的指南或出版物多针对临床遗传学或生物医学研究环境中的胚系或肿瘤测序。
- 已显示实验室间肿瘤测序分析流程存在很大差异。
- DNA测序可能产生敏感且潜在相关的数据,如临床显著的非预期发现。
关键数值与推荐
- 为成功且负责任地在临床癌症诊疗中使用DNA测序,必须满足若干道德要求,例如与遗传结果的解释和返回、知情同意以及遗传数据用于生物医学研究的回顾性和未来使用相关的要求。
临床怎么用
- 病理学家应负责分子分析的适当使用,并充分认识和处理肿瘤DNA测序的伦理问题。
- 现有临床遗传学领域的学术成果可经适当调整后转化至分子病理学,并可作为指南制定的基础。
局限性
- 本文为视角文章,未报告系统检索范围或样本量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Molecular pathology is becoming an increasingly important discipline in oncology as molecular tumor characteristics will increasingly determine targeted clinical cancer care. In recent years, many technological advances have taken place that contributed to the development of molecular pathology. However, attention to ethical aspects has been lagging behind as illustrated by the lack of publications or professional guidelines. Existing guidelines or publications on ethical aspects of DNA sequencing are mostly aimed at germline or tumor sequencing in clinical genetics or biomedical research settings. As a result, large differences have been demonstrated in the process of tumor sequencing analysis between laboratories. In this perspective we discuss the ethical issues to consider in molecular pathology by following the process of tumor DNA sequencing analysis from the preanalytical to postanalytical phase. For the successful and responsible use of DNA sequencing in clinical cancer care, several moral requirements must be met, for example, those related to the interpretation and returning of genetic results, informed consent, and the retrospective as well as future use of genetic data for biomedical research. Many ethical issues are new to pathology or more stringent than in current practice because DNA sequencing could yield sensitive and potentially relevant data, such as clinically significant unsolicited findings. The context of molecular pathology is unique and complex, but many issues are similar to those applicable to clinical genetics. As such, existing scholarship in this discipline may be translated to molecular pathology with some adaptations and could serve as a basis for guideline development. For responsible use and further development of clinical cancer care, we recommend that pathologists take responsibility for the adequate use of molecular analyses and be fully aware and capable of dealing with the diverse, complex, and challenging aspects of tumor DNA sequencing, including its ethical issues. Copyright © 2018 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
引用
- Vos S, van Diest PJ, Ausems MG, et al. Ethical considerations for modern molecular pathology. J Pathol. 2018. PMID: 30125358. doi:10.1002/path.5157
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。